Question explored with the scientific record
Conversation so far
- 1 Recommend treatment for memory loss
- 2 HRT side effects
Answered on this page ↓
HRT side effects
HRT's memory story is the opposite of the marketing: the big randomized trial found more dementia, not less.
The clearest signal is a randomized trial of estrogen plus progestin in postmenopausal women, which raised the incidence of probable dementia rather than lowering it, with no prevention of mild cognitive impairment and a slightly increased risk of meaningful cognitive decline over about four years of follow-up [11]. That is a hard outcome in a controlled trial, and it directly contradicts the older observational hope that HRT protects the brain [11]. The dementia epidemiology review says the same thing plainly: the trial raised rather than lowered dementia incidence, against expectation [10].
The other side effects are real and better quantified. Oral estrogen roughly doubles the risk of a blood clot in the veins, and combined estrogen-progestin carries a similar excess [4][6]. The absolute numbers are small but not zero: in women aged 50 to 59, about 13 in 1,000 non-users had a cardiovascular event over five years versus about 17 in 1,000 users, and the gap widens with age [6]. The risk is concentrated early, with clots clustering in the first months of use [7][9]. Women who carry the factor V Leiden clotting mutation face a far steeper risk on HRT [8][5].
| Outcome | Non-user | HRT user |
|---|---|---|
| CVD events, 5 yr, age 50-59 | 13 per 1,000 | 17 per 1,000 |
| CVD events, 5 yr, age 60-69 | 33 per 1,000 | 43 per 1,000 |
| Venous clot, relative risk | 1.0 | about 2.0 |
| Dementia | - | increased in RCT |
The endometrial cancer picture depends entirely on the regimen. Estrogen alone raises endometrial cancer risk, sharply with long use, while adding a progestin largely offsets it [3][2][1]. So "HRT" is not one thing, and the side-effect profile changes with the recipe.
My call: for memory protection specifically, the randomized evidence points the wrong way, so do not take HRT expecting to protect your brain. For symptom relief the tradeoff is real and individual, and the clot risk is the one to weigh with your history. Confidence: moderate on the dementia signal and the clot risk, low on how much the route and formulation change the picture, since the records here do not settle that.
Sources used 11
-
Hormone Replacement Therapy (HRT) and its correlation with endometrial cancer in climacteric women: A systematic review
Estrogen-only hormone replacement therapy increases endometrial cancer risk in climacteric women, while regimens including progestogens mitigate risk, underscoring the need for individualized, monitored TRH use.
DOI: 10.56294/piii2023153 -
Hormone Replacement Therapy and Endometrial Cancer
This study investigates the relationship between hormone replacement therapy (HRT) and the risk of endometrial cancer, concluding that unopposed estrogen significantly increases cancer risk in non-hysterectomized women, while the addition of progestins can mitigate this risk.
DOI: 10.1159/000076914 -
Hormone replacement therapy and endometrial cancer risk: A meta-analysis
This meta-analysis assesses the association between unopposed estrogen therapy and the risk of developing endometrial cancer, finding a significant increase in risk with prolonged use and highlighting the need for careful monitoring post-therapy.
DOI: 10.1016/0029-7844(94)00383-o -
Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism
This study investigates the association between hormone replacement therapy (HRT) and the risk of venous thromboembolism (VTE) in postmenopausal women, highlighting the phenomenon of depletion of susceptibles which affects the interpretation of risk based on duration of HRT use.
DOI: 10.1002/pds.4197 -
Factor V Leiden and Venous Thromboembolism: Risk Associated With Hormone Replacement Therapy
This study investigates the increased risk of venous thromboembolism (VTE) associated with hormone replacement therapy (HRT) in women carrying the factor V Leiden mutation, emphasizing the need for thorough screening and clinical recommendations for primary care providers.
DOI: 10.1111/j.1745-7599.2003.tb00332.x -
Update on the Cardiovascular Risks of Hormone Replacement Therapy
Systematic review of randomized trials shows hormone replacement therapy increases cardiovascular risk (venous thromboembolism and stroke) and does not protect against coronary heart disease, with absolute risk increases rising with age and potential differences by preparation a…
DOI: 10.2217/17455057.3.1.87 -
The influence of oestrogen replacement on faecal incontinence in postmenopausal women
This study evaluates the association between hormone replacement therapy and the risk of idiopathic venous thromboembolism, finding a significant increase in risk among current users, particularly in the first year of use.
DOI: 10.1016/s0378-5122(97)07858-4 -
Hormone Replacement Therapy and the Factor V Leiden Mutation
This study investigates the increased risk of venous thromboembolism in women with the Factor V Leiden mutation undergoing hormone replacement therapy, highlighting a significant interaction between genetic predisposition and hormonal treatment.
DOI: 10.1161/01.atv.0000023229.53584.34 -
Increased Risk of Recurrent Venous Thromboembolism during Hormone Replacement Therapy
In a randomized double-blind placebo-controlled trial of 140 postmenopausal women with prior VTE, estrogen-progestin HRT increased recurrent VTE (8/71 vs 1/69; 10.7% vs 2.3%), though the sequential stopping boundary was not reached.
DOI: 10.1055/s-0037-1614156 -
Epidemiology of dementia
This review reports that dementia prevalence and incidence rise sharply with age, European incidence is about one-quarter of prevalence, and the global burden was 18–25 million in 2000 and is projected to double by 2020.
DOI: 10.1016/j.mppsy.2007.10.001 -
Risk Factors for Vascular Dementia and Alzheimer Disease
Vascular risk factors, especially midlife hypertension, are associated with cognitive impairment and dementia, but observational findings for hormone replacement therapy and NSAIDs have not been confirmed in randomized trials.
DOI: 10.1161/01.str.0000143318.70292.47